Kathryn Moore Lab
@KathrynMooreLab
Followers
2K
Following
731
Media
60
Statuses
271
Studying the crosstalk of inflammation, cardiovascular disease, and RNA biology @NYULangone
New York, NY
Joined May 2018
So fun to collaborate with @GiannarelliL on this! This discovery opens new possibilities for understanding cardiovascular risks in cancer survivors and the role of immune checkpoints in atherosclerosis 🎯 @ICOSociety @CardioOncology
0
3
13
FASCIN1+ DCs in mouse and human plaques are a key target of immunotherapies linked to accelerated atherosclerotic plaque progression and increased risk of stroke and myocardial infarction in cancer survivors. #CardioOncology
1
2
8
🚨 New discovery alert! 🚨.In this month’s issue of @NatureCVR, we identify a dendritic cell population that acts as a hub for immune checkpoint communication within human atherosclerotic plaques. @NYULHCVRC @ChiaraGiannare1 .
1
18
65
We’re proud to be #1 in New York for Cardiology, Heart & Vascular Surgery, according to U.S. News & World Report! @nyugrossman @NYULHCVRC
0
0
28
Honored to receive the Grand Prix Scientifique of the Fondation Lefoulon-Delalande - @InstitutFrance with Chris Glass.
6
0
70
RT @ChiefSciCan: Thrilled to see the outstanding contributions of the 2 recipients of the @InstitutFrance Grand Prix Scientifique Lefoulon….
0
4
0
0
2
32
What a fantastic meeting! #VascularDiscovery24 community is the best.
Closing the session with reverse #CardioOncology with Richard Von Itter from @KathrynMooreLab #VascularDiscovery24 @AHAScience
1
1
31
Check out Poster #2007 at #VascularDiscovery24 to learn how ischemic injury accelerates breast cancer. @aacnewman13
0
5
28
Big day for MooreLab at #VascularDiscovery24! @FazliBozal is competing for the Investigator in Training Award & @aacnewman13 for Emerging Scientist Award for Women Award. 🤞.
1
1
9
I am honored to share the @InstitutFrance Grand Prix Scientifique de la Fondation Lefoulon-Delalande with Chris Glass (UCSD). Merci!.
Director of the CVRC, Kathryn Moore wins prestigious Grand Prix Scientifique de la Fondation Lefoulon- Delalande.
12
6
91
RT @MireilleOuimet: Beyond excited that @KateyRayner was appointed to be the next CSO of the @HeartInstitute! In addition to being a stella….
0
7
0
We show the therapeutic potential of 4-OI for reducing CVD inflammation in humans through CyTOF and scRNAseq using a systems immunology approach (5/5)
0
0
8
Treatment of mice with advanced atherosclerosis using an itaconate derivative, 4-OI, led to beneficial plaque remodeling, highlighting its potential as a novel therapeutic strategy (4/5)
1
0
5
Mechanistic studies revealed that the IRG1-Itaconate axis is crucial for reducing cholesterol-induced proinflammatory interactions between neutrophils and macrophages that prime and activate the NLRP3 inflammasome and increases IL-1b secretion (3/5)
1
0
5
Using mouse models of Irg1 deficiency, we show that loss of this pathways aggravates atherosclerosis, increasing plaque size, macrophage content, and inflammatory signaling including IL-1b (2/5)
1
0
7
We show that the enzyme IRG1/ACOD1, responsible for producing the immunomodulatory metabolite itaconate, is expressed in human and mouse atherosclerotic plaques. Intriguingly, its expression decreases with disease progression suggesting loss of this protective mechanism (1/5)
1
2
15